您当前所在的位置:首页 > 产品中心 > 产品信息
Hexobarbital_分子结构_CAS_56-29-1)
点击图片或这里关闭

Hexobarbital

产品号 DB01355 公司名称 DrugBank
CAS号 56-29-1 公司网站 http://www.ualberta.ca/
分子式 C12H16N2O3 电 话 (780) 492-3111
分子量 236.26704 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 1183

产品价格信息

请登录

产品别名

标题
Hexobarbital
IUPAC标准名
5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
IUPAC传统名
hexobarbital
商标名
Sombulex
Sombucaps
Citopan
Evipan
Noctivane
Somnalert
Evipal
Cyclopan
Cyclopal
Barbidorm
别名
5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid
Hexobarbitone
Methexenyl
Methylhexabital

产品登记号

CAS号 56-29-1

产品性质

疏水性(logP) 1.98 [SANGSTER (1994)]

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A barbiturate that is effective as a hypnotic and sedative. [PubChem]
Indication For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.
Pharmacology Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days.
Toxicity Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic.
Protein Binding 25%
References
Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases] Yakugaku Zasshi. 2004 Dec;124(12):857-71. [Pubmed]
Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8. [Pubmed]
Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7. [Pubmed]
Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6. [Pubmed]
External Links
Wikipedia

参考文献

  • Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases] Yakugaku Zasshi. 2004 Dec;124(12):857-71. Pubmed
  • Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8. Pubmed
  • Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7. Pubmed
  • Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6. Pubmed